has selected a preclinical development candidate from its allosteric Akt inhibitor program. Akt, a component of the PI3K pathway, is associated with driving tumor growth in many cancer types. ALM301, a potent, subtype selective Akt1 & Akt2 inhibitor, has demonstrated efficacy in prostate, breast and other cancer models, both as a single agent and in combination with other chemotherapeutic agents.
Effects on tumor growth inhibition in these studies also correlate with Akt pathway biomarkers. Preclinical development activities are scheduled to start early in 2013. Almac Discovery is currently seeking partners for the continued development and commercialization of ALM301 on a global basis.